Table 1.
Characteristics of 14 included studies
| Study (y) | Design | Country | Sample type | Sample size, N | Male (%) | DGF, N (%) | Donor type (DCD/ECD,%) | Donor age, year (DGF/Non-DGF) | Donor Scr, umol/l (DGF/Non-DGF) | CIT, min (DGF/Non-DGF) | NGAL, mg/ml (DGF/Non-DGF) |
DGF definitions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urine NGAL | ||||||||||||
| Parikh (2006) [8] | PC | USA | Urine | 30 | 46.7 | 10 (33.3) | 56.6 | NR | NR | 1176 ± 612/990 ± 336 | 3360 (17–5850)/ 756 (12–2500)# | Dialysis within 1 week |
| Hall (2010) [9] | PC | USA | Urine | 91 | 63 | 34 (37.4) | 100 | NR | NR | NR | 1035 (95–3134)/NR | Dialysis within 1 week |
| Hollmen (2011) [11] | PC | Finland | Urine | 176 | 62.5 | 66 (37.5) | 100 | 56 (9–75)/ 49 (9–75)* | 64 ± 17/63 ± 21 | 1374 ± 216/1278 ± 222* | 931 ± 715.1/NR | Dialysis within 1 week |
| Kanter (2013) [21] | PC | Spain | Urine | 38 | 52.6 | 15 (39.5) | 37.5 | 54 ± 12/43 ± 14 | NR | 1038 ± 342/1044 ± 228 | 275 (152–634)/92 (51–444) | Dialysis within 1 week |
| Fonseca (2013) [14] | PC | Spain | Urine | 40 | 65.0 | 18 (45.0) | 7.5 | 51 ± 13/51 ± 10 | 75 ± 19/69 ± 14 | 912 ± 468/576 ± 438 | 834 (510–2632)/80 (29–138) | Dialysis within 1 week |
| Cui (2015) [17] | PC | China | Urine | 123 | 68.3 | 21 (17.1) | 100 | NR | NR | 720 (600–840) /600 (540–780) | 657 (299–1624)/38 (11–120) | Dialysis within 1 week or Scr decreased by < 10% per day |
| Lacquaniti (2016) [18] | PC | Italy | Urine | 29 | 58.6 | 22 (75.9) | 100 | 64 ± 8/25 ± 13* | 115 ± 61/71 ± 18* | 966 ± 246/456 ± 90* | 136 ± 93/47 ± 40 | Dialysis within 1 week or Scr decreased by < 10% per day |
| Nieto-Rios (2016) [19] | PC | Clombia | Urine | 79 | 55.7 | 13 (16.5) | 100 | 27 (24–42)/26 (19–41) | 71 (60–85)/71 (53–97) | 1092 ± 402/852 ± 329* | NR/NR | Dialysis within 1 week or Scr decreased by < 10% per day |
| Summary | – | – | – | 606 | 59.1 | 199 (32.8) | 82.4 | 53.6/41.2 | 75.9/66.5 | 1121.2/907.7 | – | – |
| Blood NGAL | ||||||||||||
| Bataille (2011) [10] | PC | France | Plasma | 41 | 63.4 | 15 (36.6) | 95.1 | 43 (42–51)/55 (39–63) | 126 (86–150)/80 (50–90) | 735 (575–797)/889 (662–1020) | 571 (467–634)/242 (158–199) | Dialysis within 1 week |
| Lee (2012) [13] | RC | Korea | Serum | 59 | 59.3 | 14 (23.7) | 52.5 | 45 ± 11/41 ± 11 | NR | 337 ± 132/311 ± 107 | 490 (238–723)/184 (145–233) | Dialysis within 1 week or pathologic findings |
| Kusaka (2012) [12] | RC | Japan | Serum | 67 | 71.6 | 13 (19.4) | 41.8 | 47 (15–69)/54 | NR | 556 (162–972)/310 | NR/757 ± 58 | Dialysis within 1 week |
| Hollmen (2014) [15] | PC | Finland | Serum | 176 | 62.5 | 66 (37.5) | 100 | 56 ± 12/49 ± 15* | 64 ± 17/63 ± 21 | 1374 ± 216/1278 ± 222* | 588 ± 190/355 ± 166 | Dialysis within 1 week |
| Cantaluppi (2015) [16] | PC | Italy | Plasma | 50 | 42 | 14 (28.0) | 100 | 65 ± 9/68 ± 7 | 67 ± 20/70 ± 34 | 985 ± 237/1032 ± 177 | 663 ± 97/380 ± 140 | Dialysis within 1 week |
| Pezeshgi (2016) [20] | PC | Iran | Plasma | 37 | 59.5 | 12 (32.4) | NR | NR | NR | NR | 437 ± 164/252 ± 58 | NR |
| Summary | – | – | – | 430 | 60.9 | 134 (31.2) | 75.9 | 53.2/51.8 | 74.2/67.0 | 1044.6/854.5 | – | – |
| P value | – | – | – | 0.846 | 0.885 | 0.330 | 0.892 | 0.339 | 0.936 | 0.423 | – | – |
PC Prospective cohort, RC Retrospective cohort, NR not reported
*P < 0.05 between DGF and non-DGF groups; # ng/mg; P value for the comparison between uNGAL studies and bNGAL studies